Consensus Altimmune, Inc.

Equities

ALT

US02155H2004

Real-time Estimate Cboe BZX 10:22:12 2024-07-17 EDT 5-day change 1st Jan Change
7.78 USD -3.95% Intraday chart for Altimmune, Inc. +4.48% -30.53%

Evolution of the average Target Price on Altimmune, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c3f4bd0b29a93b3ed506ad106.2EAeEYmZel--6EbIJM6Lg3maovZQ0ipGPao3XM5y-Kg.7zJTUtj6JTDypRenHYjuyy3fzJRkp3IRStgaLP0UucvoIVsn--8fbdW-fg~9049f6dd3356158f4a6dfb543ac1ceda
Altimmune Shares Decline After Guggenheim Downgrade MT
Guggenheim Downgrades Altimmune to Neutral From Buy MT
B. Riley Raises Altimmune's PT to $20 From $15 on Increased Obesity+NASH Therapeutics' Product Sales Projections; Keeps Buy Rating MT
B. Riley Lowers Altimmune's PT to 8 From $15, Says Updated Model Adjusts for Ongoing Obesity+NASH Market Dynamics; Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Altimmune to $15 From $50, Maintains Buy Rating MT
B. Riley Lowers Altimmune's Price Target to $15 From $20, Keeps Buy Rating MT
B. Riley Lowers Altimmune's Price Target to $20 From $26, Keeps Buy Rating MT
Goldman Sachs Downgrades Altimmune to Neutral From Buy, Adjusts Price Target to $6 From $20 MT
HC Wainwright Reiterates Altimmune at Buy With $50 Price Target MT
Evercore ISI Adjusts Altimmune Price Target to $25 From $14, Maintains Outperform Rating MT
Goldman Sachs Initiates Altimmune at Buy With $20 Price Target MT
JMP Securities Adjusts Price Target on Altimmune to $26 From $28, Maintains Market Outperform Rating MT
Guggenheim Adjusts Altimmune's Price Target to $26 From $31, Reiterates Buy Rating MT
Jefferies Adjusts Altimmune's Price Target to $35 From $30, Reiterates Buy Rating MT
HC Wainwright Adjusts Altimmune's Price Target to $50 From $25, Reiterates Buy Rating MT
B. Riley Securities Raises Altimmune's Price Target to $26 from $21, Increases Likelihood of Technical, Regulatory Success; Keeps Buy Rating MT
Piper Sandler Adjusts Altimmune's Price Target to $25 From $34, Reiterates Overweight Rating MT
Guggenheim Adjusts Altimmune's Price Target to $28 From $33, Reiterates Buy Rating MT
B. Riley Lowers Altimmune's Price Target to $21 from $27 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
ALTIMMUNE : Piper Sandler Adjusts Altimmune's Price Target to $34 from $16, Keeps Overweight Rating MT
ALTIMMUNE : B. Riley Raises Altimmune's PT to $27 from $21 Ahead of 12-Week Weight Loss Readout from ALT-801 Study, Keeps Buy Rating MT
ALTIMMUNE : Jefferies Adjusts Altimmune's Price Target to $30 From $14, Reiterates Buy Rating MT
ALTIMMUNE : Guggenheim Adjusts Altimmune's Price Target to $42 From $52, Reiterates Buy Rating MT
ALTIMMUNE : HC Wainwright Adjusts Altimmune's Price Target to $25 From $35, Reiterates Buy Rating MT
ALTIMMUNE : Piper Sandler Adjusts Altimmune's Price Target to $16 From $80, Reiterates Overweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
8.1 USD
Average target price
20.57 USD
Spread / Average Target
+153.97%
High Price Target
28 USD
Spread / Highest target
+245.68%
Low Price Target
10 USD
Spread / Lowest Target
+23.46%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Altimmune, Inc.

Guggenheim
B. Riley
HC Wainwright
Goldman Sachs
Evercore ISI
JMP Securities
Jefferies & Co.
Piper Sandler
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
  1. Stock Market
  2. Equities
  3. ALT Stock
  4. Consensus Altimmune, Inc.